Company intelligence / Profile preview

LTV

Natick, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

LTV Therapeutics is a preclinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company utilizes its proprietary Linker-Toxin-Vehicle (LTV) platform to engineer ADCs with improved therapeutic indices, aiming to overcome the limitations of traditional ADC technologies. By optimizing the combination of targeting vehicles, stable linkers, and potent payloads, LTV Therapeutics seeks to deliver highly specific and effective therapies for solid tumors. The company is led by an experienced management team with deep expertise in drug development and oncology.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on LTV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTV.

Explore the full profile